Home > Insider Trading > Filing (0001178913-12-000620)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1451980	Biocancell Therapeutics Inc.	BICL	Pharmaceutical Preparations (2834)	204630076

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
919593	Idb Holding Corp Ltd	666 Third Avenue, 5Th Floor New York NY 10017	No	No	Yes	No
919594	Idb Development Corp Ltd	511 Fifth Avenue New York NY 10017	No	No	Yes	No
1051856	Ltd Investments & Industries Clal	3 Azrieli Center, Triangle Tower 45Th Floor Tel Aviv L3 67023	No	No	Yes	No
1355204	Nochi Dankner	3 Azrieli Center 44Th Floor Tel Aviv L3 67023	No	No	Yes	No
1355205	Shelly Bergman	9 Hamishmar Ha'Ezrachi Street Afeka Tel Aviv L3 69697	No	No	Yes	No
1355206	Ruth Manor	26 Hagderot Street Savyon L3 56526	No	No	Yes	No
1355207	Avraham Livnat	Taavura Junction Ramle L3 72102	No	No	Yes	No
1468950	Ltd. Industries Biotechnology Clal	Hogi Tower, 12A Abba Hillel Silver St. Tel Aviv L3 67023	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-01-24	8,199,400	$0.26	12,444,237	No	4	P	Direct
Common Stock	Acquisiton	2012-01-24	410,392	$0.00	12,444,237	No	4	J	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	J	Direct

Footnotes

As more particularly described in the Statement on Schedule 13D (the "Schedule 13D") filed by Clal Biotechnology Industries Ltd. and the other reporting persons identified therein with the United States Securities and Exchange Commission on the date hereof, the 8,199,400 shares of Common Stock reported acquired herein were acquired through a private placement that was executed in New Israeli Shekel ("NIS") at a price of NIS 1.00 per share. The price indicated in the table is based on the exchange rate of NIS and US dollar reported by the Bank of Israel on March 6, 2012 (NIS 3.814 for US$1.00).
As more particularly described in the Schedule 13D, as a result of the transaction (see footnote 1 above), the 410,392 shares of Common Stock were issued for no consideration pursuant to contractual anti-dilution undertakings of the Issuer in its Subscription and Registration Rights Agreement with Clal Biotechnology Industries Ltd., dated June 22, 2008.